PCV20 as Fourth Dose in 1-2 Year Olds
No, you should not give PCV20 as the fourth dose to a healthy 1-2 year old child who has received three prior doses of pneumococcal conjugate vaccine—instead, complete the series with PCV13 or PCV15 according to current ACIP recommendations, as PCV20 is not yet routinely recommended for the pediatric primary series. 1
Current Standard Recommendations
The ACIP recommends a 4-dose series of PCV13 at ages 2,4,6, and 12-15 months for all healthy infants. 1 For children aged 12-23 months who have received 3 doses of any pneumococcal conjugate vaccine before age 12 months, one additional dose should be administered at least 8 weeks after the most recent dose to complete the series. 1
PCV20 Pediatric Evidence and Approval Status
While PCV20 has been studied and shown to be safe and immunogenic in children:
- FDA approval exists for PCV20 in children 6 weeks through 17 years of age 2
- Clinical trial data demonstrate that a 4-dose series of PCV20 (at 2,4,6, and 12-15 months) is well-tolerated and elicits robust immune responses to all 20 serotypes 3
- Safety profile is similar to PCV13, with local reactions in 10-20% and fever ≥38°C in 15-25% of recipients 3
However, current ACIP guidelines have not yet incorporated PCV20 into routine pediatric vaccination schedules—the most recent comprehensive ACIP recommendations (2010) address PCV13, not PCV20. 1, 4
Practical Approach for Your Patient
For a healthy child aged 1-2 years with 3 prior PCV doses:
- Administer one dose of PCV13 (or PCV15 if available and preferred by local guidelines) at least 8 weeks after the third dose 1
- This completes the standard 4-dose series and provides protection against the 13 vaccine serotypes 1
- Do not substitute PCV20 for the fourth dose until ACIP formally updates recommendations to include PCV20 in the routine pediatric schedule 4, 5
Special Circumstances
For high-risk children (immunocompromising conditions, functional/anatomic asplenia, cochlear implants, CSF leaks):
- Complete the PCV13 series first, then consider additional pneumococcal vaccination per ACIP high-risk guidelines 4, 5
- These children may require PPSV23 after age 2 years, administered at least 8 weeks after completing PCV13 4, 5
Key Pitfalls to Avoid
- Do not use PPSV23 in children <2 years of age—it is not immunogenic in this age group 4, 5
- Do not delay the fourth dose waiting for PCV20 availability or guideline updates—complete the series with available PCV13/PCV15 1
- Do not restart the series if doses were delayed—simply continue from where the child left off 1, 5
- Do not give routine PCV to healthy children ≥5 years of age unless they have high-risk conditions 4, 5
Why This Matters for Outcomes
Completing the 4-dose series is critical for optimal protection: the routine 4-dose PCV13 series demonstrates 97.4% efficacy against invasive pneumococcal disease caused by vaccine serotypes. 4 Children who receive only 3 doses before age 12 months have reduced protection (87% effectiveness) compared to those completing the full series. 6 The fourth dose provides essential booster immunity that maintains protection throughout childhood. 1, 4